The British journal of clinical practice
-
Chronic non-malignant pain is often treated inadequately because of opiophobia. There is no scientific justification for this fear. ⋯ There is no scientific evidence that patients with chronic non-malignant pain are more prone to addiction or tolerance. It is also pertinent to consider that the endpoint of chronic pain treatment is not just freedom from pain but global wellbeing.
-
Case Reports
Acute psychosis associated with abrupt withdrawal of carbamazepine following intoxication.
Carbamazepine is regularly used in the treatment of trigeminal neuralgia. Although exacerbation of psychosis has been described following abrupt discontinuation of carbamazepine in chronic schizophrenics, a withdrawal syndrome has not been reported previously in patients treated for trigeminal neuralgia. The case presented here suggests that abrupt withdrawal of toxic concentrations of carbamazepine may precipitate a withdrawal reaction, which is manifest some days after discontinuation of the drug. Therefore it may be advisable to withdraw therapy slowly in these situations.
-
Focal lymphoid hyperplasia of the terminal ileum is a rare cause of terminal ileitis. We describe the case of a 13-year-old boy with a stricture of the terminal ileum that was diagnosed as Crohn's disease on barium meal and follow through. This failed to resolve on steroid therapy and the boy eventually required resection of his terminal ileum. Pathology of the terminal ileum showed focal lymphoid hyperplasia and not Crohn's disease.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol.
This 24-hour, randomised, double-blind, placebo-controlled study compared the efficacy and tolerability of intravenous injections of lornoxicam 4 mg and 8 mg with tramadol 50 mg in 78 female patients aged 20-65 years with moderate to intolerable postoperative pain following mainly hysterectomy. Patients who received lornoxicam 8 mg had a significantly (p < 0.05) longer time to first remedication than placebo recipients and tended to have a greater reduction in pain intensity and a longer time to withdrawal due to "non-response' than tramadol and placebo patients. ⋯ Thus, intravenous lornoxicam at a dose of 8 mg is superior to placebo and at least as effective as intravenous tramadol 50 mg in relieving moderate to intolerable post-hysterectomy pain. Furthermore, lornoxicam seems to possess a more favourable tolerability profile than tramadol.
-
A patient with progressive supranuclear palsy who presented with psychiatric features is reported. His case illustrates the difficulty of early diagnosis of this condition. Associated psychiatric symptoms are common and may precede the occurrence of gaze palsy. Our patient's behavioural problems responded to fluoxetine.